Impact of Herpes simplex virus load and red blood cells in cerebrospinal fluid upon herpes simplex meningo-encephalitis outcome
© Poissy et al.; licensee BioMed Central Ltd. 2012
Received: 7 June 2012
Accepted: 14 December 2012
Published: 18 December 2012
Herpes simplex encephalitis (HSE) often leads to severe disability or death. Factors usually associated with outcome include Simplified Acute Physiology Score, age and delay of initiation of acyclovir treatment.
Our aim was to determine the impact of Herpes simplex virus (HSV) load in cerebrospinal fluid (CSF) upon HSE outcome.
We retrospectively determined HSV load in the CSF of 43 patients with confirmed HSE, hospitalized in northern France from 1998 to 2005, using CSF samples collected the day of hospital admission and stored at −20°C. We analyzed the association between HSV load and mortality/morbidity by the Glasgow Outcome Scale. Fisher’s exact test and Wilcoxon’s test were used for statistical analysis.
The M/F sex ratio was 1.7 and median patient age was 61 years. Median HSV load in CSF was 2.0 log copies/μL (IQR 25-75=1.2-2.6). The mortality rate was 32.6% six months after HSE diagnosis. Higher age was associated with mortality (p=0.03). Longer delay in acyclovir initiation tended to be associated with higher mortality but did not reach statistical significance (p=0.08). Severe disability and death due to HSV were associated with a higher Knaus score (p=0.004), later acyclovir initiation (p=0.006), older age (p=0.04) and presence of red blood cells in CSF (p=0.05). HSV load in CSF was neither associated with mortality (p=1.00) nor with morbidity (p=0.90).
In this study, HSV load in CSF was not found to be associated with poor outcome in patients with HSE. These data do not support measurement of HSV load at admission in patients with HSE.
KeywordsHerpes virus Prognosis Neurological/brain Viral load
Herpes simplex virus (HSV) is the primary cause of viral necrotizing encephalitis in developed countries; when untreated, the disease has a 70% mortality rate [1, 2]. Despite the introduction of acyclovir treatment, mortality and persistent neurologic impairment due to HSV encephalitis (HSE) remain high [3, 4]: 15 to 20% of patients with HSE die and about 60% of surviving patients develop long-term neurological sequels [1, 5]. Therefore, it is important to identify factors associated with severe morbidity and mortality in HSE.
Factors commonly reported to be associated with HSE outcome are age, level of consciousness at initial management of the patient  and time to start of acyclovir treatment . Previous histopathological descriptions of HSE also showed a relationship between a high number of viral particles upon brain biopsy and poor disease outcome . However, since HSV load in the cerebrospinal fluid (CSF) is not routinely determined, data on the impact of high HSV load upon HSE outcome are scarce and contradictory [8–11].
The aim of this study was to assess the association between HSV load in CSF (before initiation of acyclovir treatment) and HSE outcome.
We conducted a retrospective study in patients diagnosed with HSE in northern France from 1998 to 2005. We focused on patients for whom a CSF sample was available prior to acyclovir treatment initiation in order to assess the association between CSF HSV load and morbidity and mortality six months after HSE onset.
Data were collected retrospectively from patient medical records using a standardized questionnaire. Morbidity was assessed using the Glasgow Outcome Scale (GOS) divided into 5 categories (1: good recovery without neurologic impairment; 2: mild disability; 3: moderate disability; 4: severe disability; 5: death) [12, 13]. The following informations were collected: i) at treatment initiation in the hospital: age, sex, alcohol consumption, severity of underlying disease, body temperature and Glasgow coma scale (GCS ); ii) during patient stay in the hospital: CSF cell counts prior to acyclovir initiation and time period between hospital admission, lumbar puncture and acyclovir initiation. Severity of the underlying disease was determined using the Knaus scale (A: normal health status; B: moderate limitation (impossible to work or study); C: severe limitation (need to have a third person in daily life); D: bedridden patient) and the MacCabe score (0: no fatal disease; 1: death in the next five years; 2: death in the following year) [14, 15].
Measurement of HSV load in CSF
HSV load was measured in CSF of patients with HSE using a frozen sample taken before acyclovir treatment was initiated. Samples were prospectively collected and stored at −20°C. When frozen CSF was available (n=30), we extracted HSV DNA using the QIAamp® DNA Blood Qiagen kit according to the manufacturer’s instructions. We performed the extraction and quantified HSV load on 200 μL of the sample for 6 patients and less than 200 μL for 24 patients. When no CSF was available to extract DNA (n=13), we quantified the viral load directly on DNA that had been extracted on the date of sampling and stored frozen at −20°C. Then, quantification of the viral load was performed using the artus® HSV-1/2 LC PCR kit manufactured by Qiagen. This PCR kit uses real time PCR for quantification and contains a second system of heterologous amplification to monitor for the possible presence of inhibitors. It allows the distinction between HSV1 and 2.
First, we used descriptive statistics to evaluate patient characteristics according to CSF sample availability. Secondly, we assessed univariate associations between HSV load (or other variables collected) and HSE outcome defined as mortality at six months and morbidity at six months (low morbidity: GOS 1, 2 and 3 versus high morbidity: GOS 4 and 5).
Non-parametric tests were used for all comparisons. Fisher’s exact test and Wilcoxon’s test were used to compare qualitative and quantitative variables, respectively. A significance threshold of 0.05 was retained. Statistical analysis was performed using SAS software (SAS 9.1, SAS Institute Inc., Cary, NC, USA).
All patients included in the study were followed in different hospitals from northern France. The care practices included CSF sampling for diagnosis and management of these patients with suspected HSE. HSV qualitative PCR were performed routinely for this diagnosis. We performed quantitative PCR retrospectively on the residual frozen CSF. No additional sampling was necessary. This study was approved by the “Comité de Protection des Personnes Nord Ouest IV”, the ethic committee of Lille Universitary Hospital.
Results and discussion
Characteristics of patients with CSF sample in our cohort
Patients with CSF sample (n=43)
Age in years (median, [IQR])
Sex (n, % of males)
Death at 6 months (n, %)
Glasgow Outcome Scale, GOS (n, %)
Good recovery to moderate disability (1–3)
Severe disability and death (4–5)
MacCabe score (n, %)
No fatal disease (0)
Death in the next 1 or 5 years (1–2)
Knaus score (n, %)
Normal health status (A)
Moderate limitation to bedridden patients (B-D)
Time to acyclovir initiation in days (median, [IQR])
Alcohol consumption (n, %)
Body temperature (°C) (median, [IQR])
GCS score (median, [IQR])
Leukocyte count (cells/μL) (median, [IQR])
Lymphocyte percentage of white cells (median, [IQR])
Time to lumbar puncture (days) (median, [IQR])
HSV load (log10 copies/μL) (median, [IQR])
Univariate analysis of factors associated with HSE mortality and morbidity
Low (n=17) GOS 1-3
High (n=22) GOS 4-5
Median HSV load (Log10 copies/μL)
Age in years (median)
Knaus score (%)
Normal health status (A)
Moderate limitation in bedridden patients (B-D)
Lymphocytic CSF (%)
Median blood red cell counts in CSF (cells/μL)
Median time to lumbar puncture (days)
Median time to acyclovir initiation (days)
We assessed factors associated with HSE outcome in 43 patients with symptomatic HSV encephalitis who sought care in northern France between 1998 and 2005. To our knowledge, this cohort is the largest ever used for evaluating the impact of HSV load in CSF upon HSV encephalitis outcome. Moreover, we used a technique of quantitative real time PCR, limiting the risks of false positive samples. We found no association between HSV load and HSE outcome, nor in mortality or morbidity six months after HSE onset.
Our results are consistent with other studies concerning factors usually associated with poor outcome in HSV encephalitis: older age, delayed initiation of acyclovir treatment and a high Knaus score [1, 2, 5, 6, 17, 18].
Regarding the absence of association between CSF HSV load and HSE outcome, our results are in contrast to results reported by Dominges et al.. However, in that study, HSV load was studied as a dichotomous variable with a cut-off of 100 copies/μL separating high and low viral load levels. In our study, we analyzed the relationship between viral load and outcome, introducing viral load as a continuous variable. Our results are in agreement with Wildeman et al., Ruzek et al. and Hjalmarsson A et al. . Kamei S et al., who evaluated serial changes of intrathecal viral loads by chemiluminescence assay and nested PCR, did not find any evident association between viral load and outcome either . Our results are also concordant with the study of Schloss et al., comparing nested PCR to quantitative real-time PCR . However, in that recently published study, not all patients were treated by acyclovir. In our cohort, all patients were treated by acyclovir and all samples were collected before introduction of antiviral treatment.
The absence of an association between HSE outcome and CSF HSV load could suggest that the pathogenicity of HSE may not be directly linked to extent of viral replication, but rather depends on the host response. This hypothesis is consistent with the fact that IgG levels were described to be significantly higher in patients with good prognostic than in patients with poor outcome .
Surprisingly, in our study, we found a significant association between a high red cell count in CSF and severe morbidity. To our knowledge, this association had not been described previously. It can be hypothesized that a higher red cell count in CSF could reflect more severe brain cell necrosis, which may be due to an intense and inappropriate immunological response of the host to viral aggression. Some experimental data suggested that an intense and inappropriate inflammatory response could be harmful, and might explain the higher risk of morbidity [22, 23]. However, this hypothesis remains to be further elucidated.
Our study had several limitations. First, although our sample size was greater than in other studies [8, 10, 11], the number of patients with available CSF samples was still small. This limitation is due to the low prevalence of HSE. Thus, due to the lack of statistical power, we may not have identified a potentially existing association between HSV load and HSE outcome. However, we were able to identify factors that are usually reported to be associated with poor HSV outcome in the literature [1, 2, 5, 6]. Second, the risk of selection bias occurrence in our study was low. Although not all patients with HSE were enrolled, those with and without available CSF samples did not statistically differ in their main characteristics. We observed a higher mortality rate in patients with available CSF samples than in those without. The reason for this difference in mortality is unclear. However, this did not bias our findings regarding the impact of HSV load on HSV outcome. Third, ideally, the impact of CSF HSV load on HSV encephalitis should be examined at the onset of first symptoms. This is, however, unfeasible and unrealistic. Finally, it can be speculated that retrospective determination of HSV load in frozen samples is not accurate and may lead to the absence of an association between viral load and HSE outcome. However, Revello et al. showed the absence of genetic matter loss in samples frozen at −20°C . Jerome et al., measured HSV loads in the same samples directly after sampling and after storage at 4°C for 16 months. HSV loads in freshly analyzed samples did not differ from those that had been stored at 4°C . It is to note that in this last study, three positive specimens were negative upon retesting after storage. All these samples contained very low levels of virus even in the original quantitation and the authors estimated that the negative results may represent the inherent inaccuracy of quantitation of viral DNA in samples with low levels of virus rather than a true loss of viral DNA. In our study, we found 5 negative samples by quantitative PCR, although they were positive with qualitative PCR. We think that we encountered the same phenomenon as Jerome et al.: accurate quantitation of viral DNA is not possible in samples with low levels of virus. In addition, we sometimes had to work with low quantities of CSF due to limited availability of samples. This occurred more frequently in patients whose samples gave negative results by quantitative PCR. In one of these 5 patients, enough CSF was available to re-perform a real time qualitative PCR, which was positive at the 39th cycle, corresponding to a low viral load. Thus, we can consider that these false negative results by quantitative PCR do not bias our results, because they effectively correspond to low HSV loads.
In the present study, we found no relationship between poor outcome in patients suffering from HSV encephalitis and HSV load in CSF prior to acyclovir treatment initiation. But we found a relation between poor outcome and the presence of red blood cells in CSF. Our results suggest that, in herpetic meningo-encephalitis, severity is probably not due to the intensity of viral replication. Whether it is related to other physiopathological causes, such as intense and inappropriate inflammatory responses, remains to be elucidated. According to our results and that of similar studies, quantitative real-time PCR is not useful to diagnose HSE. Qualitative real-time PCR assay is perfectly suited.
Herpes simplex encephalitis
Herpes simplex virus
We acknowledge Dr Ilka Engelmann for editing the manuscript.
- Whitley RJ: Viral encephalitis. N Engl J Med. 1990, 323 (4): 242-250. 10.1056/NEJM199007263230406.View ArticlePubMed
- Whitley RJ: Herpes simplex encephalitis: adolescents and adults. Antiviral Res. 2006, 71 (2–3): 141-148.View ArticlePubMed
- Gordon B, Selnes OA, Hart J, Hanley DF, Whitley RJ: Long-term cognitive sequelae of acyclovir-treated herpes simplex encephalitis. Arch Neurol. 1990, 47 (6): 646-647. 10.1001/archneur.1990.00530060054017.View ArticlePubMed
- Kapur N, Barker S, Burrows EH, Ellison D, Brice J, Illis LS, Scholey K, Colbourn C, Wilson B, Loates M: Herpes simplex encephalitis: long term magnetic resonance imaging and neuropsychological profile. J Neurol Neurosurg Psychiatry. 1994, 57 (11): 1334-1342. 10.1136/jnnp.57.11.1334.PubMed CentralView ArticlePubMed
- Raschilas F, Wolff M, Delatour F, Chaffaut C, De Broucker T, Chevret S, Lebon P, Canton P, Rozenberg F: Outcome of and prognostic factors for herpes simplex encephalitis in adult patients: results of a multicenter study. Clin Infect Dis. 2002, 35 (3): 254-260. 10.1086/341405.View ArticlePubMed
- Whitley RJ, Alford CA, Hirsch MS, Schooley RT, Luby JP, Aoki FY, Hanley D, Nahmias AJ, Soong SJ: Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med. 1986, 314 (3): 144-149. 10.1056/NEJM198601163140303.View ArticlePubMed
- Nahmias AJ, Whitley RJ, Visintine AN, Takei Y, Alford CA: Herpes simplex virus encephalitis: laboratory evaluations and their diagnostic significance. J Infect Dis. 1982, 145 (6): 829-836. 10.1093/infdis/145.6.829.View ArticlePubMed
- Domingues RB, Lakeman FD, Mayo MS, Whitley RJ: Application of competitive PCR to cerebrospinal fluid samples from patients with herpes simplex encephalitis. J Clin Microbiol. 1998, 36 (8): 2229-2234.PubMed CentralPubMed
- Revello MG, Baldanti F, Sarasini A, Zella D, Zavattoni M, Gerna G: Quantitation of herpes simplex virus DNA in cerebrospinal fluid of patients with herpes simplex encephalitis by the polymerase chain reaction. Clin Diagn Virol. 1997, 7 (3): 183-191. 10.1016/S0928-0197(97)00269-9.View ArticlePubMed
- Wildemann B, Ehrhart K, Storch-Hagenlocher B, Meyding-Lamade U, Steinvorth S, Hacke W, Haas J: Quantitation of herpes simplex virus type 1 DNA in cells of cerebrospinal fluid of patients with herpes simplex virus encephalitis. Neurology. 1997, 48 (5): 1341-1346. 10.1212/WNL.48.5.1341.View ArticlePubMed
- Ruzek D, Piskunova N, Zampachova E: High variability in viral load in cerebrospinal fluid from patients with herpes simplex and varicella-zoster infections of the central nervous system. Clin Microbiol Infect. 2007, 13 (12): 1217-1219. 10.1111/j.1469-0691.2007.01831.x.View ArticlePubMed
- Jennett B, Bond M: Assessment of outcome after severe brain damage. Lancet. 1975, 1 (7905): 480-484.View ArticlePubMed
- Teasdale G, Jennett B: Assessment of coma and impaired consciousness. A practical scale. Lancet. 1974, 2 (7872): 81-84.PubMed
- Knaus WA, Zimmerman JE, Wagner DP, Draper EA, Lawrence DE: APACHE-acute physiology and chronic health evaluation: a physiologically based classification system. Crit Care Med. 1981, 9 (8): 591-597. 10.1097/00003246-198108000-00008.View ArticlePubMed
- Mac Cabe W, Jackson W: Gram negative bacteriema: etiology and ecology. Arch Intern Med. 1962, 110: 83-91. 10.1001/archinte.1962.03620190085013.View Article
- Poissy J, Wolff M, Dewilde A, Rozenberg F, Raschilas F, Blas M, Georges H, Chaffaut C, Yazdanpanah Y: Factors associated with delay to acyclovir administration in 184 patients with herpes simplex virus encephalitis. Clin Microbiol Infect. 2009, 15 (6): 560-564. 10.1111/j.1469-0691.2009.02735.x.View ArticlePubMed
- Whitley R, Arvin A, Prober C, Burchett S, Corey L, Powell D, Plotkin S, Starr S, Alford C, Connor J, et al: A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med. 1991, 324 (7): 444-449. 10.1056/NEJM199102143240703.View ArticlePubMed
- Whitley RJ, Soong SJ, Dolin R, Galasso GJ, Ch'ien LT, Alford CA: Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis. National Institute of Allergy and Infectious Diseases collaborative antiviral study. N Engl J Med. 1977, 297 (6): 289-294. 10.1056/NEJM197708112970601.View ArticlePubMed
- Hjalmarsson A, Granath F, Forsgren M, Brytting M, Blomqvist P, Skoldenberg B: Prognostic value of intrathecal antibody production and DNA viral load in cerebrospinal fluid of patients with herpes simplex encephalitis. J Neurol. 2009, 256 (8): 1243-1251. 10.1007/s00415-009-5106-6.View ArticlePubMed
- Kamei S, Takasu T, Morishima T, Mizutani T: Serial changes of intrathecal viral loads evaluated by chemiluminescence assay and nested PCR with aciclovir treatment in herpes simplex virus encephalitis. Intern Med. 2004, 43 (9): 796-801. 10.2169/internalmedicine.43.796.View ArticlePubMed
- Schloss L, Falk KI, Skoog E, Brytting M, Linde A, Aurelius E: Monitoring of herpes simplex virus DNA types 1 and 2 viral load in cerebrospinal fluid by real-time PCR in patients with herpes simplex encephalitis. J Med Virol. 2009, 81 (8): 1432-1437. 10.1002/jmv.21563.View ArticlePubMed
- Kurt-Jones EA, Belko J, Yu C, Newburger PE, Wang J, Chan M, Knipe DM, Finberg RW: The role of toll-like receptors in herpes simplex infection in neonates. J Infect Dis. 2005, 191 (5): 746-748. 10.1086/427339.View ArticlePubMed
- Kurt-Jones EA, Chan M, Zhou S, Wang J, Reed G, Bronson R, Arnold MM, Knipe DM, Finberg RW: Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis. Proc Natl Acad Sci U S A. 2004, 101 (5): 1315-1320. 10.1073/pnas.0308057100.PubMed CentralView ArticlePubMed
- Jerome KR, Huang ML, Wald A, Selke S, Corey L: Quantitative stability of DNA after extended storage of clinical specimens as determined by real-time PCR. J Clin Microbiol. 2002, 40 (7): 2609-2611. 10.1128/JCM.40.7.2609-2611.2002.PubMed CentralView ArticlePubMed
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/12/356/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.